Prognostic importance of 18F-fiuorodeoxyglucose uptake by positron emission tomography for stage III non-small cell lung cancer treated with definitive chemoradiotherapy

Basit Öğe Kaydı
dc.contributor.authorKanyilmaz, G.
dc.contributor.authorYavuz, B. Benli
dc.contributor.authorAktan, M.
dc.contributor.authorSahin, O.
dc.date.accessioned2024-02-23T14:13:41Z
dc.date.available2024-02-23T14:13:41Z
dc.date.issued2020
dc.departmentNEÜen_US
dc.description.abstractObjectives: Survival heterogeneity exists among patients with non-small cell lung cancer (NSCLC), even within the same stage. We aimed to evaluate the prognostic role of pre-treatment maximum standardized uptake value (SUVmax) in patients treated with definitive concurrent chemoradiotherapy for stage III NSCLC. Materials and methods: Between 2010 and 2017, 103 patients with stage III NSCLC who underwent F-18-FDG PET/CT at the time of diagnosis were included in the study. Results: Higher tumor stages were correlated with higher pre-treatment SUVmax of lymph nodes (LNs) (p = 0.005) but were not correlated with higher SUVmax of primary tumor (p = 0.2). The median SUV max of LNs was 2.84, 8.06, and 11.11 in stage IIIa, IIIb and IIIc, respectively. Higher nodal stage was also correlated with higher SUVmax of LNs (p - 0.01). According to ROC analysis, there was no significant cut-off value of SUVmax observed for primary tumor, therefore continuous variables were used for survival analyses. The best SUVmax cut-off was 3.5 for the LNs, therefore the SUVmax of LNs was evaluated as both a dichotomous and a continuous variable. Pre-treatment SUVmax of primary tumor did not predict survival outcomes but both the continuous and dichotomous variables of SUV(max )of LNs predicted recurrence free survival and overall survival. Nodal stage (N0-2 vs. N3) and AJCC stage (IIIa vs IIIb vs. IIIc) were the other prognostic factors. Conclusions: Pre-treatment SUVmax of LNs had prognostic value in patients treated with definitive concurrent chemoradiotherapy for stage III NSCLC. In future trials, pre-treatment SUVmax of the LNs would serve as a guide for patients who might benefit from more aggressive treatments. (C) 2019 Published by Elsevier Espana, S.L.U. on behalf of Sociedad Espanola de Medicina Nuclear e lmagen Molecular.en_US
dc.identifier.doi10.1016/j.remn.2019.04.006
dc.identifier.endpage26en_US
dc.identifier.issn2253-654X
dc.identifier.issue1en_US
dc.identifier.pmid31668790en_US
dc.identifier.scopus2-s2.0-85074521846en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage20en_US
dc.identifier.urihttps://doi.org/10.1016/j.remn.2019.04.006
dc.identifier.urihttps://hdl.handle.net/20.500.12452/12533
dc.identifier.volume39en_US
dc.identifier.wosWOS:000531163900005en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isospen_US
dc.publisherElsevier Espana Sluen_US
dc.relation.ispartofRevista Espanola De Medicina Nuclear E Imagen Molecularen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectNon-Small Cell Lung Canceren_US
dc.subjectPet/Cten_US
dc.subjectChemoradiotherapyen_US
dc.subjectPrognosisen_US
dc.titlePrognostic importance of 18F-fiuorodeoxyglucose uptake by positron emission tomography for stage III non-small cell lung cancer treated with definitive chemoradiotherapyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu